RINVOQ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). RINVOQ may be used as monotherapy or in combination with MTX or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
Starting patients on RINVOQ: Helpful information
This convenient guide helps educate you on starting patients on RINVOQ, with information on dosing plus screening, monitoring, and safety recommendations.
RINVOQ HCP educational brochure
[Affiliate to insert link to localized version of HCP Educational Brochure from RMP from PV]
Practical guides for monitoring your patients
Find more focused information on herpes zoster, infections, and venous thromboembolic events (VTEs).
Support for your patients, every step of the way
Personalized support services, tailored to your patients' needs
We offer a range of services for your patients to help support them.
Find out more about patient support services.
TITLE OF EVENT
Subhead
Date | Location
[Affiliates to insert congresses and meetings as approved by local guidance.]
TITLE OF EVENT
Subhead
Date | Location
[Affiliates to insert congresses and meetings as approved by local guidance.]
I want to receive more information via a product specialist.
I have a question for Medical Information.